LAWSUITS FILED AGAINST AEP, FLDM and MESO - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / October 9, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

American Electric Power Company, Inc. (NYSE:AEP)

CONTACT JAKUBOWITZ ABOUT AEP:
https://claimyourloss.com/securities/american-electric-power-company-inc-loss-submission-form/?id=9988&from=1

Class Period : November 2, 2016 - July 24, 2020

Lead Plaintiff Deadline : October 19, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company covertly participated in the "the largest public corruption case in Ohio history"; (2) the Company secretly funneled substantial funds to Ohio political organizations and politicians to bribe politicians to pass Ohio House Bill 6 ("HB6"), which benefited the Company and its coal-fired generation assets; (3) the Company partially funded a massive, misleading advertising campaign in support of HB6 and in opposition to a ballot initiative to repeal HB6 by passing substantial sums through a web of dark money entities and front companies in order to conceal the Company's involvement; (4) the Company aided in subverting a citizens' ballot initiative to repeal HB6; (5) as a result of the foregoing, defendants' statements regarding the Company's regulatory and legislative efforts were materially false and misleading; 6) as a result of the foregoing, the Company would face increased scrutiny; (7) the Company was subject to undisclosed risk of reputational, legal, and financial harm; (8) the bribery scheme would jeopardize the benefits the Company sought brought by HB6; (9) as opposed to the its repeated public statements regarding a move to clean energy, the Company sought a dirty energy bailout; (10) as opposed to the Company's repeated public statements regarding protection of its customers' interests, the Company sought an extra and state-mandated surcharge on its customers' bills; and (11) as a result of the foregoing, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Fluidigm Corporation (NASDAQ:FLDM)

CONTACT JAKUBOWITZ ABOUT FLDM:
https://claimyourloss.com/securities/fluidigm-corporation-loss-submission-form/?id=9988&from=1

Class Period : February 7, 2019 - November 5, 2019

Lead Plaintiff Deadline : November 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Mesoblast Limited (NASDAQ:MESO)

CONTACT JAKUBOWITZ ABOUT MESO:
https://claimyourloss.com/securities/mesoblast-limited-loss-submission-form/?id=9988&from=1

Class Period : April 16, 2019 - October 1, 2020

Lead Plaintiff Deadline : December 7, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Jakubowitz Law
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:
https://www.accesswire.com/609964/LAWSUITS-FILED-AGAINST-AEP-FLDM-and-MESO--Jakubowitz-Law-Pursues-Shareholders-Claims